Gelonghui, April 11, 丨 Haite Biotech (300683.SZ) announced that its subsidiary, Wuhan Haite Biotech Innovative Pharmaceutical Research Co., Ltd., recently received the “Drug Clinical Trial Approval Notice” for HKG-320 injection approved and issued by the State Drug Administration.
HKG-320 injection is a potassium-channel acid blocker (P-CAB) that can reversibly inhibit the acidification function of proton pumps by competing with potassium ions on proton pumps (resting pumps and active pumps). It is clinically intended to reduce the risk of upper gastrointestinal bleeding caused by acute gastric and/or duodenal ulcers in adults after endoscopic treatment. This product is an improved new drug with “2.2 new dosage forms containing known active ingredients” and “2.4 new indications containing known active ingredients”.